INTRODUCTION {#S1}
============

Rhabdoid tumors (RTs) are aggressive pediatric cancers that primarily affect infants, accounting for approximately 15% of all infant cancer incidence in the United States and United Kingdom ([@R55]; [@R8]). RTs can arise throughout the body and are broadly classified based on the anatomical site of occurrence, i.e., atypical teratoid RTs (ATRTs) from the central nervous system (CNS) and malignant RTs (MRTs), such as RTs of the kidney (RTKs), from non-CNS tissues. Regardless of anatomical sites, RTs share pathognomonic loss of SMARCB1 (or SMARCA4 in rare cases; [@R76]; [@R26]), which encodes a core subunit of the SWI/SNF chromatin-remodeling complex that plays critical roles in epigenetic and transcriptional regulation. Apart from *SMARCB1* mutations, RTs otherwise exhibit few mutations, and in general have diploid genomes ([@R42]; [@R16]; [@R38]).

Despite being driven by SMARCB1 loss, RTs exhibit heterogeneity, with molecular subgroups identified in each of MRTs and ATRTs ([@R16]; [@R38]; [@R72]; [@R53]). In ATRTs, the SHH, TYR, and MYC DNA methylation subgroups have been described ([@R38]; corresponding to Groups 1, 2A, and 2B, respectively, in [@R72]). In MRTs, two gene expression subgroups were described (Group 1 and Group 2), which exhibited ATRT-like and RTK-like gene expression profiles, respectively ([@R16]). From these studies, some genes and pathways have emerged as commonly dysregulated across subgroups, such as the expression of *HOX* genes and other homeobox-containing genes in the ATRT-MYC subgroup and some MRTs and genes involved in neural or neural crest development in other MRTs. The existence of these shared features stimulated our hypothesis that MRT and ATRT subgroups might share additional similarities stemming from SMARCB1/SMARCA4 loss, the identification of which might improve our understanding of RT biology and ultimately reveal much needed insights into RT therapeutic vulnerabilities.

To explore this hypothesis, we performed integrative analyses of genome, transcriptome, and epigenome profiles of 301 RTs from multiple anatomic sites to reveal consensus molecular subgroups of RTs and identify shared molecular features.

RESULTS {#S2}
=======

To facilitate comparisons across RTs, we combined our previously published ATRT and MRT datasets from 40 MRTs and 150 ATRTs ([@R16]; [@R38]) and generated additional data from 11 ATRTs and 100 MRTs. The expanded datasets consist of whole-genome sequencing (WGS), transcriptome sequencing (RNA-seq), whole-genome bisulfite sequencing (WGBS), and DNA methylation array data as well as H3K27me3 and H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq) data ([Table S1](#SD3){ref-type="supplementary-material"}). In total, we analyzed data from 301 RT cases, including 161 ATRTs and 140 MRTs, of which 92 cases were from kidneys (RTKs) and 44 were from non-kidney tissues (4 cases were from unknown tissue types; [Table S1](#SD3){ref-type="supplementary-material"}).

ATRT-MYC and MRT Share Similar DNA Methylation Profiles Distinct from ATRT-SHH and -TYR {#S3}
---------------------------------------------------------------------------------------

DNA methylation profiling has been used to identify molecular subgroups in many cancer types ([@R70]; [@R12]; [@R13]; [@R58]). To identify and confirm molecular subgroups in RTs, we analyzed DNA methylation array data from 301 RT cases by using unsupervised clustering and dimension reduction algorithms ([STAR Methods](#S11){ref-type="sec"}). Results from multiple algorithms substantiated the previous observation that ATRTs formed three distinct clusters ([@R38]) and revealed a distinct cluster of ATRT-MYC and MRT cases separate from ATRT-SHH and -TYR subgroups ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). To evaluate the robustness of this clustering solution in the context of diverse cancer types, we compared DNA methylation profiles of RTs to 33 adult and 4 pediatric cancer types and 23 normal tissue types from TCGA and TARGET (n = 10,232 cases) by using an unsupervised clustering approach. MRT and ATRT-MYC again clustered together ([Figure S1](#SD1){ref-type="supplementary-material"}). Notably, RTs clustered with cancers of neural crest origin (neuroblastomas, uveal melanomas, pheochromocytomas, and paragangliomas), brain cancers (glioblastomas and low-grade gliomas) and normal brain tissues, consistent with our previous observation based on microRNA (miRNA) profiles ([@R16]).

ATRT-MYC and MRT Cases Can Be Further Separated into Three DNA Methylation Subgroups That Correlate with Anatomical Sites and *SMARCB1* Mutation Patterns {#S4}
---------------------------------------------------------------------------------------------------------------------------------------------------------

A non-negative matrix factorization (NMF) analysis ([@R21]) of DNA methylation array data revealed further separation of the ATRT-MYC and MRT group into three subgroups (Groups 1, 3, and 4), which were consistently identified using hierarchical clustering and t-Distributed Stochastic Neighbor Embedding (t-SNE) methods ([Figures 2A](#F2){ref-type="fig"}, [S2A](#SD1){ref-type="supplementary-material"}, and [S2D](#SD1){ref-type="supplementary-material"}). Although NMF results indicated that Group 1 cases could be further separated into two subgroups ([Figures 2B](#F2){ref-type="fig"}, [S2B](#SD1){ref-type="supplementary-material"}, and [S2C](#SD1){ref-type="supplementary-material"}), we did not find molecular or clinical correlates that would support the existence of biologically relevant subgroups within Group 1. We, thus, fixed our analyses on five DNA methylation subgroups, which consisted of the previously defined ATRT-SHH and -TYR ([@R38]) and three previously undefined subgroups containing MRT and ATRT-MYC cases ([Figure 2A](#F2){ref-type="fig"}).

The "ATRT-MYC-like" Group 1 (n = 67) consisted of 32 ATRT and 35 MRT cases (19 RTKs, 12 extra-renal MRTs, and 4 cases from unknown tissue types). Nearly all (31/32) ATRTs in this group were classified as ATRT-MYC. The "RTK-like" Group 3 (n = 59) consisted of 2 ATRT and 57 MRT cases, of which 53 MRT cases were RTKs. The "extra-renal MRT-like" Group 4 (n = 59) was dominated by extra-renal MRTs, containing 11 ATRT cases (6 ATRT-MYC, 4 ATRT-SHH, and 1 ATRT-TYR) and 48 MRT cases, of which 28 cases were from extra-renal tissues. The "ATRT-TYR-like" Group 2 (n = 58) mostly consisted of ATRT-TYR cases (n = 51, the remaining cases were ATRT-MYC \[n = 5\] and -SHH \[n = 2\]). The "ATRT-SHH-like" Group 5 (n = 58) consisted of ATRT-SHH cases (n = 57; one remaining case was ATRT-TYR).

We next explored the relationship between these DNA methylation subgroups and the previously described MRT gene expression subgroups ([@R16]) and observed a significant association between "RTK-like" DNA methylation Group 3 and the RTK-like gene-expression subgroup 2 (16 out of 18 cases \[89%\]; Fisher's exact p value = 0.0070; [Figure S2A](#SD1){ref-type="supplementary-material"}). In our NMF analysis that used an expanded RNA-seq dataset, including an additional 25 MRT cases ([Figures S2E](#SD1){ref-type="supplementary-material"} and [S2F](#SD1){ref-type="supplementary-material"}), we again observed a significant association between DNA methylation Group 3 and a gene expression subgroup that exclusively consisted of RTKs (24 out of 25 cases \[96%\]; Fisher's exact p value = 1.07e-05; [Figure S2E](#SD1){ref-type="supplementary-material"}).

To investigate genetic alterations that might correlate with the DNA methylation subgroups, we analyzed somatic alterations using WGS data from tumor and matched normal pairs (56 MRT and 18 ATRT cases; [Figure S3A](#SD1){ref-type="supplementary-material"}). Of 26 cases with *SMARCB1* deletions larger than 10 kilobases, a significant overrepresentation (14 out of 26 cases; Fisher's exact p value = 2.12e-08; [Figure S3C](#SD1){ref-type="supplementary-material"}) was in Group 1. Group 3 and ATRT-SHH almost exclusively contained cases with somatic nonsense mutations or focal deletions of *SMARCB1* (10 out of 12 cases and 11 out of 13 cases, respectively; [Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}). To extend our *SMARCB1* copy number analyses to cases lacking WGS data, we analyzed DNA methylation data from 301 RT cases to infer copy number alterations by using the sum of methylated and unmethylated signals ([@R70]). This analysis consistently revealed the association between larger deletions at the *SMARCB1* locus and Group 1 cases ([Figure 2C](#F2){ref-type="fig"}). As expected, genes co-deleted with *SMARCB1* (74 genes) were significantly under-expressed in Group 1 compared to other subgroups that did not harbor deletions (Wilcoxon p value = 2.59e-07; [Figure 2D](#F2){ref-type="fig"}; [Table S2](#SD4){ref-type="supplementary-material"}). Such genes included *CABIN1* (a regulator of p53 and T cell receptor (TCR) signaling), *SUSD2* (a tumor suppressor gene involved in G1 cell cycle arrest), *SPECC1L* (a regulator of craniofacial morphogenesis and cranial neural crest cell delamination; [@R77]), and *MIF* (encodes a macrophage migration inhibitory factor, involved in cell-mediated immunity and inflammation; [@R48]). The association between broad *SMARCB1* deletions and DNA methylation Group 1 is compatible with the notion that dysregulation of multiple genes in addition to *SMARCB1* may contribute to molecular subgroups.

ATRT-MYC and MRT Exhibit Global Hypomethylation and Distinct DNA Methylation Valleys Compared to ATRT-SHH and -TYR {#S5}
------------------------------------------------------------------------------------------------------------------

To compare global DNA methylation levels in MRTs and ATRTs, we analyzed WGBS data from 69 MRT and 17 ATRT cases and DNA methylation array data from 140 MRT and 161 ATRT cases. MRT and ATRT-MYC cases exhibited global DNA methylation levels that were significantly lower than ATRT-SHH and -TYR (Wilcoxon p value = 2.2e-07; [Figure 3A](#F3){ref-type="fig"}) but comparable to normal brain tissues (from 8 adult and 2 fetal brain samples; Wilcoxon p value = 0.145; [Figure S4A](#SD1){ref-type="supplementary-material"}). However, MRTs exhibited significantly lower methylation levels in introns and non-genic regions compared to normal brain samples, indicating that these regions are abnormally hypomethylated in MRTs (Wilcoxon p values = 0.011 and 8.26e-05, respectively; [Figures S4B](#SD1){ref-type="supplementary-material"} and [S4C](#SD1){ref-type="supplementary-material"}).

Our previous study ([@R38]) showed that global hypomethylation in ATRT-MYC compared to other ATRT subgroups was linked to the prevalence of partially methylated domains (PMDs). We found that PMDs were also more abundant in MRTs compared to ATRT-SHH and -TYR, covering substantial portions of the genome (Wilcoxon p value = 0.00014; [Figures 3B](#F3){ref-type="fig"} and [S4F](#SD1){ref-type="supplementary-material"}). In particular, MRTs in Groups 1 and 3 exhibited global hypomethylation associated with higher PMD fractions compared to ATRT-SHH and -TYR (Wilcoxon p value = 1.65-e07), whereas MRTs in Group 4 exhibited PMD fractions that were comparable to ATRT-SHH and -TYR ([Figures S4D](#SD1){ref-type="supplementary-material"} and [S4E](#SD1){ref-type="supplementary-material"}). This result indicated that although global hypomethylation is an epigenetic feature that is characteristic of most MRTs, Group 4 appears to have a distinct DNA methylation landscape.

To characterize candidate biological processes dysregulated by differential methylation across the subgroups, we identified differentially methylated regions (DMRs; average length = 1kb) and performed gene set enrichment analyses by using overexpressed genes in DMRs. Group 1 DMRs exhibited an unexpected enrichment for genes in immune-related pathways specifically related to interleukin 1-associated pro-inflammatory activities (e.g., *IRAK,* Toll-like receptors \[*TLRs*\], *TRAF6,* and *JNK*) that are critical for initiating innate immune responses against foreign pathogens and IRF7-associated pathways known to be activated upon viral infection ([Figure 3C](#F3){ref-type="fig"}). We also observed a significant enrichment of upregulated genes (e.g., *NCOR2,* a transcriptional repressor implicated in hematological malignancies \[[@R47]\]) in Group-1-specific DMRs involved in retinoic acid signaling, a pathway that has not been previously associated with MRTs or ATRTs ([Figure 3F](#F3){ref-type="fig"}; [Table S3](#SD5){ref-type="supplementary-material"}). Genes associated with Group-3-specific DMRs were enriched for DNA excision repair, BMP signaling, and pathways implicated in renal cell carcinoma development, consistent with RTK-like characteristics observed in Group 3 ([Figure 3D](#F3){ref-type="fig"}). For Group-4-specific DMRs, the most significantly enriched pathways included focal adhesion, FGFR signaling, and nuclear factor κB (NF-κB) signaling, a key regulatory pathway for immune and inflammatory processes ([Figure 3E](#F3){ref-type="fig"}; [@R17]).

ATRT-MYC and MRT Share Distinct Enhancer Landscapes Compared to Other ATRT Subgroups {#S6}
------------------------------------------------------------------------------------

We next investigated the extent of similarities between enhancer states in ATRTs and MRTs and analyzed H3K27ac ChIP-seq data from 34 MRT and 14 ATRT cases, of which 24 MRT cases were specifically profiled for this study. To robustly identify cases with similar H3K27ac profiles, we performed multiple iterations of unsupervised hierarchical clustering of enhancer elements defined by H3K27ac signal densities ([STAR Methods](#S11){ref-type="sec"}). Across iterations, we consistently observed clustering of ATRT-MYC with MRT cases ([Figure 4A](#F4){ref-type="fig"}), supporting the notion that ATRT-MYC and MRT share similar enhancer profiles. We also observed increased H3K27ac levels in subgroup-specific DMRs ([Figure 4B](#F4){ref-type="fig"}), further supporting upregulation of genes in these regions (e.g., *NCOR2)*.

We identified 26 dense clusters of high H3K27ac signals indicative of super-enhancers that were common between ATRT-MYC and MRT. The most prominent super-enhancer was found at the *HOXC* locus ([Figure 4C](#F4){ref-type="fig"}; [Table S4](#SD6){ref-type="supplementary-material"}), with genes at this locus exhibiting significant overexpression compared to ATRT-SHH and -TYR (Wilcoxon p values \< 2.4e-15 for *HOXC* genes and DESeq adjusted p value = 3.43e-05 for *HOTAIR;* [Figure 4D](#F4){ref-type="fig"}). There were 61 regular enhancer elements that were common between ATRT-MYC and MRT ([Table S4](#SD6){ref-type="supplementary-material"}) in the proximity of genes involved in epigenome modification and development, including *CREBBP* (encodes a histone acetyltransferase involved in embryonic development and growth control), *PRDM6* (histone methyltransferase and transcriptional repressor involved in smooth muscle differentiation), and *TINAGL1* (encodes an antigen associated with tubulointerstitial nephritis; also involved in proliferation and migration of cranial neural crest cells \[[@R52]\]).

We next studied enhancer-mediated transcriptional dysregulation by identifying transcription factors (TFs) that would likely bind to enhancer regions. We analyzed enrichment of TF binding sites (TFBSs) within enhancer regions that were unique to MRT, ATRT-MYC, -SHH, or -TYR, by calculating enrichment scores based on observed and expected numbers of TF motifs found in enhancer regions ([STAR Methods](#S11){ref-type="sec"}). Unsupervised hierarchical clustering of TF motif enrichment scores showed clustering of ATRT-MYC and MRT, implying that common factors could act on such enhancers ([Figure 4E](#F4){ref-type="fig"}). TFs known to bind to such sites included those regulating mesoderm and neural crest development, (e.g., HES7 and REST, TFs that suppress neuronal transcription programs \[[@R5]; [@R9]\]). Also enriched within ATRT-MYC and MRT was a TFBS for XBP-1, a TLR-activated TF required for production of proinflammatory cytokines ([@R50]), corroborating our DMR analysis result (above) that indicated epigenetic dysregulation of genes involved in interleukin 1-mediated signaling. In ATRT-MYC, we observed TFBS for TFs involved in apoptosis and immune regulation, such as GMEMB1/2, RAD21, IRF5/8/9, and STAT1. IRF5/8/9 are involved in the induction of type I interferons (IFNs), inflammatory cytokines and MHC class I genes and, hence, promote immune responses involving, e.g., CD8+ cytotoxic T cells and natural killer (NK) cells. Likewise, STAT1 regulates the expression of multiple IFN target genes ([@R36]). Our analyses thus indicated the unexpected possibility of immune modulation through epigenetic dysregulation in RTs.

Immune-Related Genes, *HOX* Genes, and Mesoderm Developmental Regulators Are Overexpressed in ATRT-MYC and MRT Compared to ATRT-SHH and -TYR {#S7}
--------------------------------------------------------------------------------------------------------------------------------------------

Our DNA methylation and enhancer data indicated shared epigenetic dysregulation of TFs in ATRT-MYC and MRT, potentially acting on similar gene expression programs. To identify such similarities, we performed differential gene expression analyses and identified 584 overexpressed genes and 2,500 under-expressed genes in ATRT-MYC and MRT relative to ATRT-SHH and -TYR (DESeq adjusted p values \< 0.05; [STAR Methods](#S11){ref-type="sec"}; [Figure 5A](#F5){ref-type="fig"}). The most significantly overexpressed genes in ATRT-MYC and MRT included tissue-type-specific genes (e.g., *GCG* and *KERA*) and developmental regulators of mesoderm and mesoderm-derived tissue types (e.g., *TCF21,* encoding a mesoderm-specific TF, and *DMP1* and *MEOX2*, involved in bone and vascular smooth muscle development, respectively). Notably, 26 members of all *HOX* gene families were likewise significantly overexpressed in ATRT-MYC and MRT. These results support the notion of dysregulated developmental programs, particularly those involved in mesodermal development, in ATRT-MYC and MRT. In contrast, ATRT-SHH and -TYR exhibited relative overexpression of genes involved in neural development (e.g., *SOX1, GPR98/ADGRV1*, and *OTX2),* suggesting more neural characteristics in these subgroups.

Next, we used multiple pathway databases to identify functional categories enriched for differentially expressed genes ([STAR Methods](#S11){ref-type="sec"}; [Table S5](#SD7){ref-type="supplementary-material"}). The most significantly enriched pathways, including overexpressed genes in ATRT-MYC and MRT, were developmental pathways for mesenchymal cell types and mesoderm-derived organs ([Figure 5B](#F5){ref-type="fig"}), as well as immune-related pathways, including regulation of immune system processes and innate immune responses (adjusted p values = 1.40e-04 and 0.050, respectively; [Table S5](#SD7){ref-type="supplementary-material"}). In contrast, ATRT-SHH and -TYR exhibited significantly enriched pathways that predominantly involved neural development ([Figure 5B](#F5){ref-type="fig"}), with ATRT-SHH further exhibiting a more neural-like gene expression program compared to ATRT-TYR ([Figure S5A](#SD1){ref-type="supplementary-material"}). Notably, we did not observe enrichment of immune-related functions in ATRT-SHH and -TYR. Increased expression of immune-related genes in ATRT-MYC and MRT was consistent with the enrichment of immune-related TFBSs (above), suggesting that ATRT-MYC and MRT might share an immune-related phenotype.

To further corroborate pathway enrichment results, we identified TF-regulatory networks consisting of TFs, putative direct target genes with corresponding TF motifs, and shared patterns of gene expression with TFs ([STAR Methods](#S11){ref-type="sec"}; [@R1]), integrating these by using unsupervised clustering. ATRT-MYC and MRT cases clustered together, sharing 13 common transcriptional networks distinct from ATRT-SHH and -TYR ([Figure S5C](#SD1){ref-type="supplementary-material"}). Of these, 11 involved *HOX* genes, of which five identified *MYC* as one of the putative direct HOX target genes, supporting the notion that the prominent molecular characteristics of *HOX* gene overexpression and dysregulation of *MYC*, another key characteristic of ATRT-MYC and MRT, might be linked ([Figure S5C](#SD1){ref-type="supplementary-material"}; [Table S5](#SD7){ref-type="supplementary-material"}). Another notable TF gene was *HES7,* a transcriptional repressor significantly overexpressed in ATRT-MYC and MRT (adjusted p value = 0.0036; [Figure S5B](#SD1){ref-type="supplementary-material"}), with binding sites that were enriched in ATRT-MYC and MRT enhancer regions ([Figure 4E](#F4){ref-type="fig"}). Downstream target genes of HES7, such as *LEF1* (implicated in co-activation of MITF and development of neural-crest-derived melanocytes; [@R44]), *DUSP4* (regulator of MAPK signaling), and *CTNNB1* (key component in the canonical WNT signaling pathway), exhibited significantly reduced expression in ATRT-MYC and MRT. Decreased levels of gene expression were correlated with lower H3K27ac and higher H3K27me3 levels in ATRT-MYC and MRT compared to ATRT-SHH and TYR ([Figure 5C](#F5){ref-type="fig"}), indicating overall epigenetic dysregulation of the HES7 transcriptional network. *AES*, which encodes a transcriptional co-repressor of *HES7* involved in neural, head mesenchyme, and ectoderm development, was, like *HES7,* upregulated in ATRT-MYC and MRT, further indicating distinct dysregulation of the HES7-driven transcriptional program in ATRT-MYC and MRT. TFs enriched for ATRT-SHH (e.g., NEUROD1, NHLH1, and EN2) and ATRT-TYR (OTX2 and ZIC4) included neural developmental regulators, consistent with the notion that ATRT-SHH and -TYR are more neural-like.

To determine distinct gene-expression characteristics for Groups 1, 3, and 4, we identified functional categories enriched for subgroup-specific differentially expressed genes and constructed Gene Ontology enrichment map networks. Networks of the most significantly enriched pathways for Group 1 involved early developmental processes as well as ERK/MAPK signaling ([Figure 5D](#F5){ref-type="fig"}; [Table S5](#SD7){ref-type="supplementary-material"}). Group 3 networks also involved early developmental processes in addition to cell migration, adhesion, and extra-cellular matrix organization ([Figure 5E](#F5){ref-type="fig"}). Group 4 networks exclusively consisted of immune-related categories ([Figure 5F](#F5){ref-type="fig"}). To explore the association between RT subgroups and early developmental processes, we correlated transcriptome profiles of the subgroups to various progenitor cell types ([@R41]; [@R16]; [@R60]). Among the subgroups, Group 1 showed the highest correlation to CD56+ mesodermal progenitor cells and Group 3 to embryonic stem cell lines ([Figure S5D](#SD1){ref-type="supplementary-material"}). ATRT-SHH showed the highest correlation to cranial neural crest cells, neuronal progenitors, and brain tissues, consistent with our observations of ATRT-SHH exhibiting the most neuronal-like characteristics among the subgroups.

Gene Expression Data Indicate Increased T Cell Presence in ATRT-MYC and Extra-Cranial MRT Subgroups {#S8}
---------------------------------------------------------------------------------------------------

Following our analyses that indicated epigenetic modulation of genes involved in immune-related functions, we used CIBERSORT ([@R54]) to deconvolute immune cell gene expression signatures and, thus, estimate the extent of immune cell presence. To quantify overall T cell presence in each sample, we calculated a T cell score (a sum of effector T cell proportions; [Figure 6A](#F6){ref-type="fig"}) and observed that inferred proportions of CD8+ cytotoxic T cells were among the highest in the 22 immune cell types profiled, along with tumor-associated M2 macrophages ([Figures 6C](#F6){ref-type="fig"} and [S6A](#SD1){ref-type="supplementary-material"}; [@R68]), suggesting the involvement of both pro- and anti-tumoral immune functions in the tumor microenvironment. We observed a significant over representation of Groups 1 and 4 (Fisher's exact p values = 0.018 and 5.13e-03, respectively), and a significant under-representation of Group 3 and ATRT-SHH (Fisher's exact p values = 2.13e-04 and 0.031, respectively) in cases with CD8+ T cell proportions within the top 25^th^ percentile ([Figure 6B](#F6){ref-type="fig"}). We also noted that among such cases were two ATRT-TYR cases with abundant *TBXT* expression (196.4 and 35.3 Reads Per Kilobase per Million mapped reads (RPKM), median of the cohort = 0.0021 RPKM; [Figure 6D](#F6){ref-type="fig"}), which encodes an embryonic TF (T-brachyury) that has been linked to immune responses in chordoma patients ([@R56]).

To gain insight on biological processes that might contribute to increased immune activities predicted in RT subgroups, we analyzed genes involved in T cell-mediated immune responses. We found that nearly all *HLA* genes encoding MHC class I and II (18 out of 19 genes) were significantly overexpressed in cases with CD8+ T cell proportions greater than the median (adjusted p values \< 0.05; [Figure 6E](#F6){ref-type="fig"}). Consistent with this observation, *NLRC5* and *CIITA,* which encode the master TFs that regulate MHC class I and II genes, were also significantly overexpressed in these cases (adjusted p values = 0.0001 and 0.0018, respectively). The increased expression of *HLA* genes also correlated with increased TCR diversity in these cases, represented by Shannon Wiener index scores (Welch's t test p value = 0.012; [Figure S6B](#SD1){ref-type="supplementary-material"}; [@R6]; [@R67]). The cases with increased CD8+ T cell proportions further exhibited significantly higher expression levels of key genes involved in antigen degradation, processing, and transportation ([Figure 6E](#F6){ref-type="fig"}). Such genes included *PSMB8/9/10* (which encode components of the immunoproteasome), *TAP1* (encodes a component of the transporter-associated with antigen processing complex), and *B2M* (encodes MHC class I heavy chain). Genes involved in T cell activation, homing, and infiltration were significantly overexpressed in these cases ([Figure 6F](#F6){ref-type="fig"}), such as *TNF* and *IFNG* (involved in T cell activation); *CXCL9* and *CXCL10* (encode chemokines that attract and support the influx of CD8+ T cells); and *PRF1, GZMA,* and *GZMB* (encode perforins and granzymes that are secreted by activated cytotoxic T cells). We also observed significant overexpression of *CLEC9A/DNGR-1* (adjusted p value = 0.0062), which is expressed in the CD8α+ antigen-presenting dendritic cells that are associated with T cell-infiltrated tumor microenvironments ([@R20]). Overall, these results suggested that RTs exhibiting high CD8+ T cell proportions might have inflamed tumor microenvironments with functionally active CD8+ cytotoxic T cells. Seeking to understand how RTs might survive in such inflamed microenvironments, we analyzed genes involved in T cell inhibitory functions and observed overexpression of an important T cell inhibitory cytokine gene, *IL10,* and several key immune checkpoint genes (e.g., *PDCD1/PD1, CD274/PD-L1*, and *HAVCR2/TIM3*) in the cases with CD8+ T cell proportions greater than the median (adjusted p values \< 0.05; [Figure 6G](#F6){ref-type="fig"}). We also observed a significant enrichment for overexpressed genes in these cases in the Ras/ERK/MAP kinase pathway (BH adjusted p value = 1.6e-04), known to maintain clonal anergy, an immune tolerance mechanism by which lymphocytes become functionally inactivated following an antigen encounter ([@R66]). Taken together, these observations are compatible with the notion that RTs may evade the immune system by either increasing the expression of immunosuppressive programs or reducing the expression of MHC complex components.

To understand whether the level of immune cell presence is unique to RTs compared to other pediatric cancers that occur in similar anatomical sites, we compared T cell scores in RTs to those in medulloblastomas (105 cases) and Wilms tumors (130 cases; [@R19]). We observed significantly higher proportions of T cell scores in Groups 1 and 4 and ATRT-TYR compared to medulloblastomas and Wilms tumors (Wilcoxon p values \< 0.05; [Figure 7A](#F7){ref-type="fig"}), suggesting that a subset of RTs might be more immuno-stimulated compared to other pediatric cancers of the brain and the kidney.

Immunohistochemistry Confirms Increased Cytotoxic T Cell Infiltration and Immune Checkpoint Expression in MRT and ATRT-MYC {#S9}
--------------------------------------------------------------------------------------------------------------------------

To validate our analyses and orthogonally assess the extent of immune cell infiltration in tumor tissues, we performed multiplex immunohistochemistry (IHC) profiling of 185 tumor samples from 62 patients (35 MRT cases and 27 ATRT cases) by using antibodies to identify CD8+ cytotoxic T cells (CD3+CD8+), CD4+ helper T cells (CD3+CD8−), and macrophages/microglia (CD68+). Expression of the immune checkpoint proteins, PD1 and PD-L1, was also assessed. We were able to evaluate MRT samples selected from among cases we profiled using RNA-seq or DNA methylation array data, but the ATRT samples were from a separate cohort due to a lack of availability of profiled cases. To properly assess the extent of immune cell infiltration in tumor tissues, we examined three types of regions in tumor microenvironments (total number of regions profiled = 2,979; [Table S6](#SD8){ref-type="supplementary-material"}), i.e., tumor-rich regions away from necrosis (TT; n = 1,803), peri-vascular regions surrounding vascular structures (PV; n = 591), and peri-stromal regions at the interface with benign and/or normal tissues (PS; n = 585).

Our IHC data showed higher levels of tumor-infiltrating CD3+ lymphocytes in MRT and ATRT-MYC compared to ATRT-SHH and -TYR in all regions of the tumor microenvironment (Wilcoxon p value \< 2.2e-16; [Figure S7A](#SD1){ref-type="supplementary-material"}). CD3+ lymphocyte infiltration levels were consistent with our predicted effector T cell scores (Pearson rho = 0.540, linear regression p value = 0.0025; [Figure 7B](#F7){ref-type="fig"}). CD8+ cytotoxic infiltration levels were also consistent with our predicted CD8+ proportions (Pearson rho = 0.569, linear regression p value = 0.0019; [Figure 7C](#F7){ref-type="fig"}). Also consistent with our prediction, the majority (88.6%) of tumor-infiltrating CD3+ lymphocytes in MRT and ATRT-MYC were CD8+ cytotoxic T cells ([Figures 7D](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}; \[dummy_Data S1\]). In contrast, ATRT-SHH exhibited the lowest CD3+ lymphocyte and CD8+ cytotoxic T cell infiltration, whereas ATRT-TYR showed only a trend toward increased levels of CD4+ helper T cells ([Figure S7C](#SD1){ref-type="supplementary-material"}). IHC also revealed overall increased expression of PD-L1 in MRTs compared to ATRTs (Wilcoxon p value \< 2.2e-16; [Figure 7F](#F7){ref-type="fig"}). A significant increase in PD-L1-expressing CD68+ myeloid cells was also observed in MRTs compared to ATRTs (Wilcoxon p value \< 2.2e-16; [Figures 7G](#F7){ref-type="fig"} and [S7B](#SD1){ref-type="supplementary-material"}; \[dummy_Data S1\]). MRTs in Group 4 exhibited the highest mean density of PD1-expressing lymphocytes among RT subgroups (Wilcoxon p value = 0.0002; [Figure S7D](#SD1){ref-type="supplementary-material"}). Notably, ATRT-SHH exhibited the highest median density of PD-L1-negative CD68+ myeloid cells among the five subgroups (Kruskal-Wallis p value = 9.60e-12, Dunn's adjusted p values against ATRT-SHH \< 9.46e-03; [Figure 7H](#F7){ref-type="fig"}).

Given the very low mutation load (and thus paucity of related neoantigens) in RTs, we sought to identify genes that may play a role in increased immunogenicity in RT subgroups. Considering other studies that linked epigenetic de-repression of endogenous retroviral elements (EREs) to anti-tumor immune responses ([@R14]; [@R63]), we analyzed H3K27ac and DNA methylation levels of CpGs within ERE regions (LINE, SINE, LTR, and ERV from RepeatMasker; n = 3,877,818). Although we noted a significant increase in H3K27ac signals in Groups 1, 3, and 4 compared to ATRT-SHH and -TYR (Welch's t test p value = 3.17e-05; [Figure S6G](#SD1){ref-type="supplementary-material"}), we did not observe evidence for ERE de-repression in RTs based on ERE methylation or expression levels (Welch's t test p values \> 0.05; [Figures S6C](#SD1){ref-type="supplementary-material"}--[S6H](#SD1){ref-type="supplementary-material"}). On the other hand, we identified nine known tumor antigen genes (*ABCC3, CDR2, CEACAM21*, *CEA-CAM4, DSE, EPS8, ISG15, MUC1,* and *TBXT*) whose expression levels correlated with T cell scores (linear regression p values \< 0.05). Of these, *IGS15* and *TBXT* were overexpressed in RTs compared to normal cell types ([Figure S7E](#SD1){ref-type="supplementary-material"}), suggesting that aberrantly expressed developmental genes such as these may be antigens in RTs.

DISCUSSION {#S10}
==========

Our integrative meta-analyses of multi-omic datasets revealed shared molecular characteristics between cranial ATRT-MYC and extra-cranial MRT at both global and local levels and enabled identification of five DNA methylation subgroups of RTs across multiple anatomical sites. Our epigenome and gene-expression analyses indicated the role of multiple early developmental states contributing to disease heterogeneity, based on mesoderm-like characteristics in subgroups consisting of MRT and ATRT-MYC, and neural-like characteristics in ATRT-SHH and -TYR. Although such characteristics may point to potential cells of origin, the observation of broad deletions of the *SMARCB1* locus in Group 1 cases also presents a possibility of specific genetic alterations contributing to disease heterogeneity, although detailed functional characterizations would be required to confirm this hypothesis.

Unexpectedly, several lines of evidence described in our study supported immune modulation in RTs. ATRT-MYC and MRT showed an enrichment of TFBS in the enhancers of genes involved in type I IFN-induced responses (*IRF5/8/9* and *STAT1*) and antigen presentation (*RFX1/5* and *XBP-1*). Pathway enrichment analyses using subgroup-specific differentially methylated or expressed genes (e.g., *UBD* and *AIM2*) also suggested the involvement of type I IFN-mediated signaling ([@R71]), NF-κB activation ([@R22]; [@R31]), and cytosolic DNA sensing processes that mediate viral defense as well as the maturation of dendritic cells and their ability to mediate antigen presentation ([@R75]). Our gene expression analyses further supported the notion that a subset of RTs could exhibit increased antigen presentation contributing to creating inflammatory tumor microenvironments infiltrated with functionally active cytotoxic T cells. Although our analysis did not support the notion of epigenetically de-repressed EREs as a potential source of antigens, we did observe increased tumor antigen expression from developmentally silenced genes whose expressions are normally restricted to early embryonic stages or to specific tissue types. In addition, our data were compatible with the notion that somatic deletions affecting immune modulating genes may contribute to increased cytotoxic T cell infiltration. For example, significant under-expression of *MIF* due to homozygous co-deletion with *SMARCB1* in Group1 cases may contribute to increased immunogenicity observed in this subgroup, as suggested by a previous study that demonstrated increased levels of CD8-induced tumor cytotoxicity in MIF double knockout mice compared to wild-type mice ([@R15]).

Increased infiltration of CD8+ cytotoxic T cells in MRT and ATRT-MYC tumors was directly validated using IHC. Such infiltration has been positively associated with survival and responses to immune checkpoint inhibition (ICI) in other cancer types ([@R74]; [@R4]). MRTs further exhibited increased infiltration of PD-L1+CD68+ myeloid cells, which also have been associated with favorable responses to ICI ([@R29]; [@R49]). In contrast, ATRT-SHH exhibited the highest level of PD-L1-negative CD68+ myeloid cells, the presence of which has been associated with poor prognosis of ICI ([@R29]), consistent with the observation of the lowest CD8+ T cell infiltration level observed in the ATRT-SHH subgroup.

Although ICI has emerged as a promising cancer therapy, it frequently has been described to be most effective against cancers with high mutational burdens that are thought to result in neoantigens that provide a substrate for T cell recognition ([@R65]; [@R28]). However, several recent studies indicated that mutations in the SWI/SNF complex can also increase the immunogenicity of tumors ([@R57]; [@R51]). Our observations of increased cytotoxic T cell infiltration, T cell anergy, and immunosuppressive signaling in immune-responsive MRTs and ATRT-MYC support the notion that T cells may be functionally inhibited by the effects of immune checkpoint signaling and are consistent with accumulating evidence that SWI/SNF mutations can contribute to tumor immunogenicity in ways that may enhance their vulnerability to ICI. Our analyses provoke hypotheses related to the extent of immune cell infiltration, apparent pro- and anti-tumoral immune responses in the tumor microenvironment, and the potential of immune checkpoint inhibitors applied in RT patients. Additional studies will be necessary to deduce mechanisms, but our results so far have shown epigenetic dysregulation in embryonic-development- and immune-related gene expression programs in RT subgroups, perhaps suggesting that tumors with extensive developmental gene dysregulation, which otherwise lack mutations such as RTs, may be poised for immune stimulation. These findings may thus lay the groundwork for further work to delineate whether the immune cell-inflamed phenotypes and molecular similarities between MRT and ATRT-MYC can be usefully deployed in the clinic.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcel Kool (<m.kool@kitz-heidelberg.de>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

Data from 141 primary extra-cranial MRT and 161 primary cranial ATRT samples were analyzed for this paper. Data for 40 out of 141 MRT samples were generated as part of a previous report ([@R16]). In addition to these data, 29 MRT samples (26 from kidneys, 3 from soft tissues) were provided by Dr. Elizabeth Perlman (Ann and Robert H. Lurie Children's Hospital in Chicago, USA) through the Children's Oncology Group (COG). From COG, we received pre-therapy tumor and normal DNA from peripheral blood or kidney from rhabdoid tumors (RTs), registered on the National Wilms Tumor Study Group 5 or on COG AREN03B2 banked by the COG Biopathology Center with parental informed consent. Studies were performed with the approval of the University of British Columbia - British Columbia Cancer Agency Research Ethics Board (REB number H09--02558). 9 MRT samples (3 from the spine, 2 from kidneys, remainder from various non-renal tissues e.g., pelvis, face) were provided by Dr. Annie Huang (Hospital for Sick Children in Toronto, Canada) through the Rare Brain Tumor Consortium (RBTC). An additional 63 MRT samples (31 from kidneys, 8 from the liver, remainder from various non-renal tissues e.g., retroperitoneum, Intra-abdomen, face) were provided via the EURHAB study group, with informed consent obtained from all patients included in the study. Data for 150 out of 161 ATRT samples were generated as part of a previous report ([@R38]). 11 additional ATRT-MYC samples were provided by Dr. Martin Hasselblatt. To enable as comprehensive a study as possible for this rare tumor type, we aggregated all obtainable RT samples that passed quality criteria from COG and EURHAB studies.

For samples provided through COG, Nationwide Children's Hospital prepared cells and nucleic acids, and shipped these materials to DKFZ for DNA methylation profiling and to Canada's Michael Smith Genome Sciences Centre at BC Cancer (BCGSC) for whole-genome-, whole-genome bisulfite-, RNA-, and ChIP-seq. For samples provided through DKFZ, cells and nucleic acids were prepared at various sample providers' institutions, and underwent DNA methylation profiling at DKFZ. Complete sample information, including age and sex of patient subjects, is provided in [Table S1](#SD3){ref-type="supplementary-material"}.

Tumor content was estimated for 74 cases (56 MRT and 18 ATRT cases) using whole-genome-sequencing data generated from tumor and matched normal pairs and APOLLOH software ([@R23]), as described previously ([@R16]). The median tumor purity estimated by APOLLOH was 88.31% (min = 42.78%; max = 95.04%).

METHOD DETAILS {#S14}
--------------

Procedures pertaining to previously published data have been described in [@R16] and [@R38].

### DNA Methylation Array Data Generation and Processing {#S15}

DNA methylation array data from 150 primary ATRT samples were previously published ([@R38]). DNA methylation array data from 9 MRT samples from RBTC were generated using Illumina's Infinium HumanMethylation450 BeadChip (450K) platform. Using Illumina's Infinium MethylationEPIC (850K) platform, we generated DNA methylation data for 40 primary MRT samples that previously had been analyzed using whole-genome bisulfite sequencing ([@R16]), and also for an additional 11 ATRT and 91 MRT cases. All samples were checked for expected and unexpected genotype matches by pairwise correlation of the 65 genotyping probes on the Illumina Methylation 450K array. Raw 450K/850K data files were generated and processed as previously described ([@R13]).

### Whole-Genome Library Construction and Sequencing {#S16}

Whole-genome sequencing (WGS) data from pairs of 40 primary MRT and 18 primary ATRT cases, and their corresponding matched normal samples, were previously published ([@R16]; [@R38]). We generated WGS data for an additional 16 pairs of MRT and matched normal samples. WGS library construction, sequencing, and read alignment were performed as previously described in [@R16]. In brief, all primary tumor and matched normal samples underwent plate-based PCR-free WGS on the Illumina HiSeq 2500 platform to achieve the desired sequence coverage (\> 30X). Sequences were aligned to the human reference genome GRCh37-lite/hg19a using the Burrows-Wheeler Aligner (BWA; version 0.5.7; [@R45]). Merged BAM files were marked for duplicates using Picard MarkDuplicates.jar (version 1.71).

### Whole-Transcriptome Library Construction and Sequencing {#S17}

Whole-transcriptome sequencing (RNA-seq) data from 40 primary MRT and 25 primary ATRT cases were previously published ([@R16]; [@R38]). We generated RNA-seq data for an additional 25 primary MRT cases. RNA-seq library construction and sequencing were performed as previously described in [@R16]. In brief, paired-end polyA+ RNA sequencing was performed preserving strand specificity on the Illumina HiSeq 2500 platform.

### Whole-Genome Bisulfite-seq Library Construction and Sequencing {#S18}

Whole-genome bisulfite sequencing (WGBS) data from 40 primary MRT and 17 primary ATRT cases were previously described ([@R16]; [@R38]). We generated WGBS data for an additional 29 primary MRT cases. WGBS library construction and sequencing were performed as previously described in [@R16]. In brief, fragmented bisulfite converted DNA was sequenced using paired-end 100/125 nt V3/4 sequencing chemistry on the Illumina HiSeq 2500 platform.

### Chromatin Immunoprecipitation (ChIP) Library Construction and Sequencing {#S19}

H3K27ac and H3K27me3 ChIP-seq data from 10 primary MRT and 14 primary ATRT cases were previously published ([@R16]; [@R38]). We generated H3K27ac and H3K27me3 ChIP-seq data for an additional 24 and 25 primary MRT cases, respectively. ChIP-seq library construction and sequencing were performed as previously described in [@R16]. In brief, samples were prepared from cross-linked tissues, from which ChIP was performed using the extracted chromatin. Fragmented chromatin DNA was sequenced using paired-end sequencing chemistry on the HiSeq 2000/2500 platforms.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
---------------------------------------

### Mutation Analyses using Whole-Genome Sequencing Data {#S21}

In addition to the previously described data, we analyzed whole-genome sequencing data from 18 pairs of ATRT and their matched normal samples, and 16 pairs of MRT and their matched normal samples to identify somatic mutations i.e., copy number alterations (CNA), single nucleotide variants (SNVs), short insertions and deletions (InDels), and structural variants such as inversions, duplications, and translocations that may lead to gene fusions. To allow data comparability, we used the same suite of software tools described in [@R16], including Strelka (version 2.0.7; [@R64]), SAMtools mpileup (version 0.1.17; [@R46]), and MutationSeq ([@R18]) to detect somatic SNVs and InDels, APOLLOH (version 012.2014a; [@R23]) to detect regions with loss of heterozygosity (LOH), CNASeq (version 1.0.10; [@R39]) to detect CNA, and Trans-ABySS (version 1.4.10; [@R62]) to detect structural variants such as chromosomal translocations and inversions.

### Copy Number Analysis using DNA Methylation Data {#S22}

We used the conumee R package (<http://bioconductor.org/packages/release/bioc/html/conumee.html>) to estimate the chromosomal copy number state from 450K and EPIC/850K DNA methylation array data as previously described in [@R38]. Regions with values \> 0.3 were considered to have chromosome amplifications, while regions with values \< −0.3 were considered to have chromosome deletions.

### Analysis of RNA-Seq Data {#S23}

RNA-seq read alignment and gene expression quantification for 65 MRT and 25 ATRT samples were performed using methods previously described in [@R16]. Briefly, reads were aligned to the human reference genome (version hg19/GRCh37-lite) and to exon junction sequences using BWA. JAGuaR (version 2.2.2; [@R10]) was used to reposition sequences mapped to exon junctions back onto the genome as gapped alignments. We calculated the sequenced base coverage across collapsed exon models to quantify gene-level expression using the gene coverage analysis software developed at Canada's Michael Smith Genome Sciences Centre. All external RNA-seq data (i.e., neuron progenitor data from the Roadmap Epigenomics Consortium and cranial neural crest data from [@R60]) were processed using the same software pipeline and gene annotation versions as the MRT RNA-seq data, as previously described ([@R16]).

For gene expression analyses, we selected genes that were expressed above a noise threshold of 1 RPKM in all 90 samples. 27,790 out of 58,450 genes, annotated by EnsEMBL version 69, were removed using this filter. To identify differentially expressed genes, we used the DESeq R package (version 1.14.0; R version 3.3.2; [@R2]) and an adjusted p value threshold of 0.05. For subsequent analyses, we further filtered low abundance transcripts that were identified to be overexpressed in one group compared to another group, but had a median expression level less than 1 RPKM. Pathway enrichment analysis was done using DAVID (version 6.8) ([@R34]), g:Profiler ([@R61]), Metascape ([@R73]), and Ingenuity Pathway Analysis© tool, with an adjusted p value threshold of 0.05. We used EnrichmentMap plug-in (version 3.2.0) for Cytoscape (version 3.7.1) to visualize networks of significantly enriched Gene Ontology (GO) biological processes from g:Profiler queries. Node color represents a BH-adjusted p value of enrichment tests. The size of a node is proportional to the number of genes in a biological process. The thickness of an edge is proportional to a similarity coefficient based on the fraction of shared genes between biological processes.

To cluster RT samples based on gene expression, we first removed genes expressed below 1 RPKM in ≥ 75% of samples, and then ranked the remaining genes based on the coefficient of variation. We performed unsupervised non-negative matrix factorization (NMF) using the top 25% most variably expressed genes (n = 3,984), and considered a k value i.e., a clustering solution, at which the highest cophenetic coefficient and silhouette width were observed. We used the NMF R package (version 0.20.2; [@R21]), with a default Brunet algorithm and 50 and 500 iterations for the rank survey and the clustering runs, respectively.

To deconvolute gene-expression signals originating from various immune cell types, we applied CIBERSORT analysis using the CIBERSORT R script (version 1.04; [@R54]) to gene-level RPKM data with 5,000 permutations using the absolute signature score mode. To detect T cell receptor (TCR) sequences, we used MiXCR (version 2.1.9; [@R6]) on FASTQ data generated from paired-end RNA-seq of 25 ATRT and 65 MRT cases, and identified reads that aligned to reference germline V, D, J, and C gene sequences from GenBank, which were then assembled for clonotype mapping i.e., construction of full-length CDR3 regions of the TCR. We then analyzed TCR β clonotypes generated from MiXCR to calculate Shannon Wiener index scores, which quantify the diversity of TCR repertoires in each sample using VDJTools ([@R67]).

To compare gene expression levels in RTs against various normal tissue types, we used RPKM values from the Genotype-Tissue Expression dataset (GTEx version 9; number of samples = 2,500; number of normal tissue types = 52), and from normal cerebellum (n = 9) and normal kidney (n = 6) datasets.

Transcriptional network analysis consisted of three steps, as adapted from the SCENIC pipeline ([@R1]): (1) Identify potential targets of each transcription factor (TF); (2) perform TF motif enrichment analysis to identify the putative direct targets of each TF to form a transcriptional network, and (3) score the activity of each network in each sample. Co-expression modules were constructed using the R package GENIE3 v0.99.7 ([@R35]). The input used was a gene-expression matrix consisting of genes with \>1 RPKM in all samples (n = 90; 65 MRT and 25 ATRT cases). TF-gene pairs with co-expression scores greater than 0.001 and having positive Spearman correlations were used to construct TF gene sets, each consisting of a TF and genes with co-expression patterns. TF motif enrichment analysis was then performed for each TF gene set using the R/Bioconductor package RcisTarget (version 0.99.0), which contains motif rankings for \~1800 TFs from iRegulon ([@R37]). From these, we inferred direct targets of a TF by filtering the genes that were significantly enriched for at least one of the TF's binding motifs, and generated a TF network consisting of a TF and its putative direct targets. The activity of each TF network was quantified using the R package AUCell (version 0.99.5). An area under the recovery curve (AUC) analysis was performed for each TF network identified in a sample to quantify the proportion of genes that are present within the highest-expressing genes in each sample. To identify active TF networks in each sample, a binary score indicating network activity states (1 = on/active, 0 = off/inactive) was assigned to each sample using a threshold determined based on the distribution of AUC values across all samples ([@R1]).

To quantify endogenous retroviral element (ERE) transcript abundance levels, we used reads that mapped to loci containing short or long interspersed nuclear elements (SINEs or LINEs, respectively) and long terminal repeat (LTR) retrotransposons including endogenous retroviruses (ERV), annotated by UCSC RepeatMasker (hg19 version). A list of 5,467,457 repeat elements and their genomic coordinates was obtained from RepeatMasker (version hg19 - Feb 2009 - RepeatMasker open-4.0.5 - Repeat Library 20140131; [@R69]). The list was filtered to remove EREs with uncertain annotations (i.e., those annotated with "?") and EREs on the Y and non-canonical chromosomes. We further selected EREs that did not overlap with gene promoters (includes 1500 bp upstream of a TSS) and gene bodies to obtain ERE transcript abundance levels that were not likely to be confounded by "host" gene transcription (n = 3,877,818). Raw transcript abundance levels were quantified for each ERE by counting the number of reads that mapped unambiguously, with their mate reads mapping within 10kb from a read center. ERE transcript abundance levels were normalized for a library depth, and represented in reads per million reads mapped (RPM).

### DNA Methylation Array Analysis {#S24}

We processed the raw IDAT files using the minfi R package (version 1.20.2; [@R3]) and applied the single-sample Noob (normal-exponential out-of-band) method to correct the background. To enable comparisons between 450K and the EPIC arrays, only the probes represented on both arrays were used for the analysis. In addition, the following filtering criteria were applied: Removal of probes targeting the X and Y chromosomes; removal of probes containing a single nucleotide polymorphism (dbSNP132Common) within five base pairs of and including the targeted CpG-site (n = 24,536), and removal of probes not mapping uniquely to the human reference genome (hg19), allowing for one mismatch ([@R79]).

Fort-SNE analysis, the R-package tSNE (version 0.1.3) was used. Unsupervised hierarchical clustering and Consensus Clustering were carried out as described previously with varying numbers of CpG sites ([@R38]).

To assess the extent of molecular similarities and identify subgroups of RTs, we combined DNA methylation array data generated from 161 ATRT and 140 MRT samples to perform unsupervised NMF analysis. We first filtered out CpG sites that were targeted by probes annotated to be less robust (e.g., those with SNPs) according to the published annotation ([@R79]). We also removed CpG sites with 0% methylation across all 301 samples. We considered only CpG sites on autosomes, and selected CpG sites that were positively methylated with beta-values \>0.3 in at least 10% of samples, following the methods applied by TCGA ([@R11]; [@R7]). The remaining CpG sites were then ranked using standard deviation, such that the most variably methylated CpG sites could be selected for downstream analyses. We performed unsupervised NMF using the top 10,000 CpG sites with a default Brunet algorithm and 50 and 500 iterations for the rank survey and the clustering runs, respectively.

To test for non-random distribution of covariates between subgroups of interest, we applied Fisher's exact test (using the fisher.test function in R) and performed Benjamini-Hochberg multiple hypotheses testing adjustments using the p.adjust function in R to obtain adjusted p values.

We performed hierarchical clustering (Spearman correlation coefficient as the distance metric, complete linkage clustering) on 9,758 DNA methylation profiles representing 33 tumor types (n = 9,012), 23 normal tissue types (n = 746) from TCGA, and 464 DNA methylation profiles representing four pediatric tumor types (n = 452) and 12 pediatric normal brain tissues from TARGET. We also included DNA methylation profiles from 8 normal adult and 2 fetal brain samples from DKFZ. For each cancer and normal tissue type, a median beta value for CpG probes was determined (probes were previously filtered using the method described above). These median values, together with DNA methylation profiles from primary MRT and ATRT cases, were then used for the clustering analysis. The TCGA cancer types included BRCA (n = 796; Breast invasive carcinoma); LGG (n = 534; Low-grade glioma), HNSC (n = 530; Head and neck squamous cell carcinoma), THCA (n = 515; Thyroid carcinoma), PRAD (n = 503; Prostate adenocarcinoma), LUAD (n = 475; Lung adenocarcinoma), SKCM (n = 473; Skin cutaneous melanoma), UCEC (n = 439; Uterine corpus endometrial carcinoma), BLCA (n = 419; Bladder urothelial carcinoma), STAD (n = 396; Stomach adenocarcinoma), LIHC (n = 380; Liver hepatocellular carcinoma), LUSC (n = 370; Lung squamous cell carcinoma), KIRC (n = 325; Kidney renal clear cell carcinoma), COAD (n = 316; Colon adenocarcinoma), CESC (n = 309; Cervical squamous cell carcinoma and endocervical adenocarcinoma), KIRP (n = 276; Kidney renal papillary cell carcinoma), SARC (n = 265; Sarcoma), ESCA (n = 186; Esophageal carcinoma), PAAD (n = 185; Pancreatic adenocarcinoma), PCPG (n = 184; Pheochromocytoma and paraganglioma), TGCT (n = 156; Testicular germ cell tumors), GBM (n = 153; Glioblastoma multiforme), LAML (n = 140; Acute myeloid leukemia), THYM (n = 124; Thymoma), READ (n = 99; Rectum adenocarcinoma), MESO (n = 87; Mesothelioma), UVM (n = 80; Uveal melanoma), ACC (n = 80; Adrenocortical carcinoma), KICH (n = 66; Kidney chromophobe), UCS (n = 57; Uterine carcinosarcoma), DLBC (n = 48; Diffuse large B cell lymphoma), CHOL (n = 36, Cholangiocarcinoma), and OV (n = 10; Ovarian serous cystadenocarcinoma). The TARGET cancer types included CCSK (n = 11; Clear cell sarcoma of the kidneys), NBL (n = 224; Neuroblastoma), OS (n = 86; Osteosarcoma), and WT (n = 131; Wilms tumor). The level 3 TCGA and TARGET data were generated using Illumina Human Methylation 450 platform, and were obtained through the TCGA GDC Data Portal at <https://portal.gdc.cancer.gov/> and the TARGET Data Portal at <ftp://caftpd.nci.nih.gov/pub/OCG-DCC/TARGET/>.

For hierarchical clustering, we used the hclust R package (R version 3.3.2) and clustered samples using the top 10,000 most variably methylated CpGs, using complete linkage and the Spearman correlation coefficients as the distance metrics. We also performed hierarchical clustering using the top 1% most variably methylated CpGs (n = 3,958) using complete linkage and the Pearson correlation coefficient as the distance metrics. We used the heatmap.2 function within the gplots R package (version 2.16.0) for visualization of clustering results.

### Analysis of ChIP-Seq Data {#S25}

Alignment of sequencing data was performed as described in [@R38]. In brief, BWA was used to align sequence reads. Duplicate reads were marked using Picard MarkTools. For enhancer and peak-centered analyses of H3K27ac and H3K27me3 data, we used MACS2 ([@R78]) with default settings to call peaks. Peak calling was performed for each sample in the sample cohort, and peaks that were present in two or more samples were retained for analyses. Resulting peaks were merged and used for further analyses.

The signals at peaks were calculated as previously described ([@R30]), using the "countsForRegions" function followed by scaling the counts to library size. We applied the same method to calculate H3K27ac signal at promoters, which are defined as regions ± 500 bp around the transcription start site (TSS). Peaks (enhancers) with the most variable signal across all MRT samples were chosen. For unsupervised hierarchical clustering, the top 1,500 most variable peaks over all samples were used.

For TF enrichment analyses, enhancers specific to MRTs were defined based on statistical testing of MRT enhancers versus all enhancers specific to the three ATRT subgroups characterized in our previous report ([@R38]). Briefly, we applied ANOVA with an FDR cut-off of 0.05 and required at least log2 fold change of 1.5 between MRT and ATRT enhancer signals. Nucleosome free regions (NFRs) of these specific enhancers were identified using the HOMER software (<http://homer.ucsd.edu/homer/>; version 4.10; [@R27]). For TF enrichment, the ENCODE motifs were downloaded from <http://compbio.mit.edu/encode-motifs/>. Each motif was overlapped with the NFRs from MRT-specific enhancers. Chi-square tests were applied to identify significantly enriched TF motifs (FDR \< 0.01). Enrichment values for ATRT subgroup-specific enhancers were taken from previous analyses ([@R38]).

### Identification of Super-Enhancers and Target Genes of Super-Enhancers {#S26}

Super-enhancers were identified using the HOMER software (<http://homer.salk.edu/homer/ngs/index.html>) and the findPeaks command with "-style super" option. ATRT super-enhancers had been identified previously in [@R38]. For MRT-specific super-enhancers, H3K27ac data were combined for all MRT samples and compared to ATRT subgroups. To identify super-enhancers that were common between MRT and ATRT-MYC, we compared the coordinates of super-enhancers and selected those that overlapped by at least 25% between MRT and ATRT-MYC-specific enhancers (as defined in [@R38]), but not between MRT and other ATRT subgroup-specific enhancers.

### Analysis of WGBS Data {#S27}

WGBS data from ATRT and MRT cases were previously published ([@R16]; [@R38]). Alignment of the data was performed as previously described ([@R33]) using Bismark ([@R40]). Identification of partially methylated domains (PMDs) in MRT was performed using the same method as described in [@R38]. In brief, average methylation levels within windows of 10 kb were calculated in steps of 1 bp. Overlapping 10 kb windows with an average methylation level \< 0.6 were merged, and resulting regions larger than 100 kb were termed PMDs.

To identify differentially methylated regions (DMRs), we used the bsseq R package (version 1.18.0; [@R25]) to create the data frames for methylated reads and to calculate the whole coverage per sample based on aligned reads. A CpG site with a minimum coverage of 5 reads was selected for downstream analyses. For each sample, a bsseq object was generated, and then analyzed to identify DMRs specific for each of the five subgroups, using the callDMR function in the DSS R package (version 2.12.0; parameters used: minlen = 50, minCG = 5). To identify a gene that overlapped with DMRs, the longest transcript of a protein-coding gene was considered. For visualization of WGBS data, the GVIZR package was used (version 1.26.4; [@R24]).

### Immunohistochemistry (IHC) {#S28}

Two multi-color immunohistochemical panels were stained on whole tissue slides using two staining schemes. All reagents were sourced from Biocare Medical (Pacheco, CA) unless noted otherwise. Slides were incubated overnight at 37°C, then deparaffinized manually using xylene and graded alcohols. The slides were then subjected to antigen retrieval using a Biocare decloaking chamber plus™ at 110°C for 15 minutes in Diva decloaking solution. Slides were then loaded onto a Biocare Intellipath FLX® autostainer. The first two steps of the staining schemes required blocking of endogenous peroxidase activity using peroxidased-1 dispensed using the Intellipath FLX for 5 minutes followed by blocking of non-specific binding using a blocking reagent, background sniper, for 10 minutes. All antibodies were diluted in Biocare Da Vinci Green diluent.

For multiplex IHC targeting CD3 and CD8, we used the following staining scheme: Primary antibodies of CD8 (clone C8/144b from Cell Marque) and CD3 (clone SP7 from Spring Bioscience) were combined into a cocktail diluted in Da Vinci Green diluent at 1/250 and 1/500 dilutions, respectively, which was manually added to the slides for 30 minutes. These were then followed by Mach2 Double Stain \#2 polymer dispensed using the Intellipath FLX® for 30 minutes to put CD8 on IP DAB chromogen and CD3 on IP Warp Red chromogen. Following the chromogen step, slides were counterstained with CAT Hematoxylin at a 1/5 dilution and then washed and air-dried prior to coverslipping with Ecomount. The staining scheme for the multiplex IHC targeting PD1, PD-L1, and CD68 was done as follows: In the first round of staining, primary antibodies of PD-L1 (clone SP142 from Abcam) and CD68 (clone KP-1 from Biocare Medical) were combined into a cocktail diluted 1/100 in Da Vinci Green diluent, and applied to the slides for 30 minutes, followed by Mach2 Double Stain \#1 polymer for 30 minutes to put CD68 on IP Ferengi Blue chromogen and PD-L1 on IP DAB chromogen. The slides then underwent a denaturation step with SDS-glycine pH2.0 at 50°C for 45 minutes ([@R59]). In the second round of staining, we manually applied primary PD1 antibody (clone EPR4877(2) from Abcam) diluted 1/250 in Da Vinci diluent for 30 minutes, followed by Mach2 Rabbit-AP polymer for 30 minutes to put PD1 on IP Warp Red chromogen. Slides were then counterstained with CAT Hematoxylin at a 1/5 dilution and then washed and air-dried, followed by coverslipping with Ecomount.

### IHC Analysis {#S29}

IHC-stained slides were scanned at 10X to create whole slide scans using the Vectra 3 multispectral imaging system (Perkin Elmer, Waltham, MA). The files generated were then passed to a pathologist (B.T-C.) for selection of 15 tumor-rich (TT), 5 peri-vascular (PV), and 5 peri-stromal (PS) regions based on whole slide scans of H&E stained slides using the Pannoramic Midi system (3D Histech). Slides were then re-scanned using the Vectra 3 multispectral imaging system, generating multispectral images at 20X magnification based on the digitally annotated fields of view. Multispectral imaging enabled spectral separation between different chromogens for better visualization of images and spectral superimposition of different chromogens to identify co-expression of proteins. Multispectral images were analyzed using the inForm Image Analysis software (Perkin Elmer) to automatically identify cell phenotypes and perform cell counts. Five phenotyping algorithms were created using a training set of images (10 per algorithm) selected to recognize diverse cell phenotypes. The resulting cell counts were compared and visually validated in all cases by a researcher (H.-J.E.C). Normalized immune cell densities for each image were calculated by dividing validated cell counts by the scanned area (mm^2^; calculated by multiplying a number of pixels of the scanned image by 2.5 × 10^−7^), and were then compared across all samples. Normalized cell counts were plotted using R, and statistical significance of cell count differences was calculated using either of the Wilcoxon Mann-Whitney U or Kruskal-Wallis tests.

To enhance visibility and discrimination between IHC colors, IHC images shown in [Figure 7E](#F7){ref-type="fig"} were adjusted to reduce the blue hematoxylin signals by 50% and were re-colored with the following pseudocolors: CD8+ signals in brown and CD3+ in green. To better visualize PD-L1+ CD68+ and PD-L1− CD68+ cells, IHC images were modified as false immunofluorescence images as shown in [Figure S7B](#SD1){ref-type="supplementary-material"}, with following pseudocolors applied: CD68+ in green, PD-L1+ in red, PD1+ in cyan, and PD-L1+CD68+ in yellow. All data analyses were performed on raw images using inForm.

### Text-Mining Analysis for Identifying Putative Tumor-Associated Antigens {#S30}

In order to build a list of putative tumor antigens, we used a text-mining method ([@R43]) to extract mentions of tumor antigens found in published abstracts and full-text papers. From PubMed abstracts and all downloadable PubMed Central articles, we extracted sentences that mention the phrase "tumor antigen" (variable spellings considered) and contain a gene name from the NCBI gene list with additional synonyms. We then used an active learning approach to annotate the sentences as to whether the gene name was a potential tumor antigen. This used the Kindred relation extraction Python package ([@R43]) to train a logistic regression classifier based on dependency parse-based features. Relations that the classifier found ambiguous, which were those classified differently using a bootstrapping method, were presented to an *in silico* annotator. This annotation provided a training set to train a final relational classifier that was applied to all relevant sentences and used to build a list of putative tumor antigens that was then reviewed manually. All code is accessible at <https://github.com/jakelever/tumorantigens>.

DATA AND CODE AVAILABILITY {#S31}
--------------------------

Raw DNA methylation array data generated from ATRT samples from DKFZ have been deposited in the Gene Expression Omnibus (GEO). The accession number for the ATRT DNA methylation array data reported in this paper is GEO: GSE123601. The accession number for raw DNA methylation array data and sequence data generated from MRT samples from TARGET reported in this paper is NCBI dbGaP: phs000470, with additional data available at <http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html>. Details for other data and software availability are in the [Key Resources Table](#T1){ref-type="table"}. Requests for additional data and code should be directed to the Lead Contact.
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![Unsupervised Clustering of DNA Methylation Profiles from 140 MRTs (92 Renal, 48 Extra-Renal) and 161 ATRTs Indicate Similarity between ATRT-MYC and MRT\
(A) t-SNE analysis was performed using the top 2,000 most variably methylated CpG sites and to reveal three clusters that consisted primarily of ATRT-MYC (n = 44 cases) and MRT (n = 140 cases), ATRT-SHH (n = 64 cases), or ATRT-TYR (n = 53 cases).\
(B) Unsupervised hierarchical clustering was performed using the top 1% most variably methylated CpG sites (n = 3,958) and yielded a clustering result consistent with (A). See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S1](#SD3){ref-type="supplementary-material"}.](nihms-1544232-f0002){#F1}

![Five DNA Methylation Subgroups of RTs from Cranial and Extra-Cranial Sites Correlate with Previously Known ATRT and MRT Subgroups, Anatomical Sites, and *SMARCB1* Deletion Patterns\
(A) Unsupervised NMF analysis was performed using the top 10,000 most variably methylated CpG sites and revealed five subgroups (top). Clinical features, gene expression subgroups of MRTs, and previously characterized ATRT subgroups are shown in colored tracks (middle). Chronological age and predicted DNA methylation age ([@R32]) are shown in bar plots (bottom). ATRT-SHH and Group 1 exhibited increased DNA methylation age compared to the other subgroups (Wilcoxon p values = 1.62e-05 and 6.30e-10 for ATRT-SHH and Group 1, respectively). Neither chronological age nor gender were significantly associated with the subgroups (Kruskal-Wallis p value = 0.25 and Fisher's exact p values = 0.16 -- 0.86, respectively).\
(B) Cophenetic coefficients (top) and silhouette widths (bottom) for NMF cluster solutions from k = 2 to k = 15. The highest cophenetic coefficients and silhouette widths were from the NMF solutions with 5 and 6 clusters.\
(C) Heatmap indicates chromosomal copy gain (indicated by red) or loss (blue), estimated using DNA methylation data, centered at the *SMARCB1* locus across the five DNA methylation subgroups (n = 301 cases).\
(D) Boxplot shows the mean expression levels of 74 genes (top) co-deleted with *SMARCB1* across the five subgroups (n = 19 cases for Group 1, n = 41 for Group 3, n = 11 for Group 4, n = 11 for ATRT-SHH, n = 8 for ATRT-TYR) and expression levels of *MIF* (bottom). The asterisk indicates a significant difference (Wilcoxon p value \< 0.05) between Group 1 and other RT subgroups.\
See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"} and [Table S2](#SD4){ref-type="supplementary-material"}.](nihms-1544232-f0003){#F2}

![ATRT-MYC and MRT Exhibit Similar DNA Methylation Profiles Distinct from ATRT-SHH and -TYR\
(A) Boxplot shows the distribution of mean genome-wide DNA methylation levels based on WGBS data. MRT (n = 69 cases) and ATRT-MYC (n = 3 cases) showed significant hypomethylation compared to ATRT-SHH (n = 7 cases) and -TYR (n = 7 cases; \*Wilcoxon p value \< 0.05).\
(B) Boxplot displays the distribution of fractions of the genome covered by PMDs in MRT and ATRT-MYC, which exhibited significantly more abundant PMDs compared to ATRT-SHH and -TYR (\*Wilcoxon p value \< 0.05).\
(C--E) Gene set enrichment of DMRs that are specific for Groups 1 (C), 3 (D), and 4 (E). The x axes indicate the statistical significance of the enrichment test. (F) Heatmap (left) shows average CpG methylation levels at the *NCOR2* locus in Group-1-specific DMRs (red = 100%; blue = 0% methylation). Boxplot (right) shows significantly increased *NCOR2* expression levels in Group 1 compared to other RT subgroups (\*Wilcoxon p value \< 0.05).\
See also [Figure S4](#SD1){ref-type="supplementary-material"} and Table S3.](nihms-1544232-f0004){#F3}

![ATRT-MYC and MRT Exhibit Distinct Enhancer Profiles\
(A) Unsupervised clustering of H3K27ac ChIP-seq read densities resulted in a cluster of ATRT-MYC cases (n = 4) and MRT cases (n = 34) indicated by green and purple bars, respectively.\
(B) Line plots show the average H3K27ac signal densities of the five RT subgroups at Group-1- (including ATRT-MYC; n = 460 DMRs), Group-3- (n = 426 DMRs), and Group-4-specific DMRs (n = 280), respectively. Subgroup-specific DMRs showed the highest H3K27ac signal density levels in the respective subgroups.\
(C) Mean H3K27ac density at the *HOXC* locus, which was specific to MRT (n = 34 cases) and ATRT-MYC (n = 4 cases) and absent in ATRT-SHH (n = 5 cases) and -TYR (n = 5 cases).\
(D) Boxplots show *HOXC* (top) and *HOTAIR* (bottom) gene expression levels, which were significantly higher in MRT cases (n = 65) and ATRT-MYC (n = 6 cases) compared to ATRT-SHH (n = 11 cases) and -TYR cases (n = 8; \* adjusted p values \< 0.05).\
(E) Unsupervised hierarchical clustering using enrichment scores of TFBS at enhancers specific to MRT (n = 312 enhancers), ATRT-MYC (n = 443 enhancers), -SHH (n = 511 enhancers), and -TYR (n = 1,385 enhancers). Heatmap colors represent the log2 enrichment scores of TFs in the enhancers. Colors next to gene names indicate known biological processes associated with TFs.\
See also [Table S4](#SD6){ref-type="supplementary-material"}.](nihms-1544232-f0005){#F4}

![Dysregulation of Mesenchymal Development Genes Is Associated with ATRT-MYC and MRT, whereas Dysregulation of Neural Genes Is Associated with ATRT-SHH and -TYR\
(A) Volcano plot shows the statistical significance of differential expression (DE; adjusted p values \< 0.05) on the y axis, and the fold change (FC) of gene expression in ATRT-MYC (n = 6 cases) and MRT (n = 65 cases) compared to ATRT-SHH (n = 11 cases) and -TYR (n = 8 cases) on the x axis. The top 20 significant DE genes, *HOX* genes, and genes involved in neural or mesenchymal development are labeled in colors as shown.\
(B) Bar plots show the most significantly enriched pathways and adjusted enrichment p values based on analyses of 584 relatively overexpressed genes (top) and 2,500 relatively under-expressed genes (bottom) in MRTs and ATRT-MYC compared to ATRT-SHH and -TYR.\
(C) Gene expression levels and H3K27ac and H3K27me3 densities (i.e., average read coverage) at the promoters of *HES7* and its interactors are shown in boxplots.\
(D-F) Enrichment map networks of Gene Ontology (GO) terms significantly enriched for Group-1- (D), Group-3- (E), and Group-4-specific (F) DE genes. A node size is proportional to the number of genes in the category and a node color indicates an adjusted enrichment p value. The edge thickness is proportional to a fraction of shared genes between GO terms.\
See also [Figure S5](#SD1){ref-type="supplementary-material"} and [Table S5](#SD7){ref-type="supplementary-material"}.](nihms-1544232-f0006){#F5}

![Gene Expression Analysis Indicates Increased T Cell Presence in RT Subgroups\
(A) Stacked bar plot shows CD8+ cytotoxic T cell proportions (yellow) and T cell scores (blue), which are based on the sum of absolute proportions of effector T cells (i.e., all T cell types except regulatory T cells \[T~Veg~\]). The samples (n = 90) are ordered based on CD8+ cytotoxic T cell proportions(and in all subsequent sub-figures in Figure 6). A subgroup of each sample is indicated in (B).\
(C) Heatmap shows absolute proportions of 22 immune cell types predicted using CIBERSORT.\
(D) Bar plot shows expression levels of the *TBXT* gene, which encodes T-brachyury.\
(E-G) Heatmaps indicate expression levels of genes involved in antigen presentation and processing (E), T cell activation and homing (F), and immunosuppressive signaling (G). All genes were significantly overexpressed in cases with CD8+ T cell proportions greater than the median (adjusted p values \< 0.05, except for *CTLA4* \[adjusted p value = 0.10\]).\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1544232-f0007){#F6}

![Comparison of T Cell Presence in RTs to Other Cancer Types and Validation of Increased T Cell Infiltration using IHC\
(A) Boxplot shows T cell scores across the five RT subgroups (19 cases from Group 1, 41 from Group 3, 11 from Group 4, 11 from ATRT-SHH, and 8 from ATRT-TYR), pediatric medulloblastomas (n = 105 cases), and Wilms tumors (n = 130; \*Wilcoxon p values \< 0.05). IHC profiling was performed on 2,979 regions selected from 185 tumor tissue slides from 35 extra-cranial MRT cases (9 from Group 1, 20 from Group 3, and 6 from Group 4) and 27 ATRT cases (10 from ATRT-MYC, 10 from ATRT-SHH, and 7 from ATRT-TYR). CD68+ myeloid cells were profiled from 915 tumor-enriched (TT), 304 peri-vascular (PV), and 297 peri-stromal (PS) regions. CD3+ lymphoid cells were profiled from 888 TT, 287 PV, and 288 PS regions.\
(B and C) Scatter plots show comparisons between T cell scores and median CD3+ leukocyte densities determined for each sample using IHC (B), as well as between CD8+ T cell proportions and median CD3+CD8+ cytotoxic T cell densities determined for each sample using IHC (C; x and y axes in log10 scale). Dashed lines indicate positive linear correlations (Pearson rho = 0.540 and 0.569, linear regression p values = 0.0025 and 0.0019 for CD3+ and CD3+CD8+ cells, respectively).\
(D) Boxplots show distributions of CD8+ cytotoxic T cell densities in tumor-enriched (TT), peri-stromal (PS), and peri-vascular (PV) regions (y axis, log10 scale). MRT cases in Groups 1, 3, and 4 and ATRT-MYC cases showed significantly higher CD8+ T cell densities compared to ATRT-SHH and -TYR in all regional types (Wilcoxon p values = 2.2e-16, 6.94e-15, and 3.84e-12, respectively).\
(E) Examples of cases with high (top) and low (bottom) T cell infiltration revealed by multiplex IHC staining (CD3+ green; CD8+ brown). Images are at 30x magnification. Scale bars: 100 μm.\
(F and G) Boxplots show distributions of overall PD-L1 + cell (F; y axis, log10 scale) and PD-L1-positive CD68+ immune cell densities (G; y axis, log10 scale). The asterisk indicates statistical significance p value \< 0.05.\
(H) Boxplot shows distributions of PD-L1-negative CD68+ immune cell densities, which are significantly higher in ATRT-SHH compared to other subgroups (\*Dunn's adjusted p value \< 0.05).\
See also [Figure S7](#SD1){ref-type="supplementary-material"} and [Table S6](#SD8){ref-type="supplementary-material"}.](nihms-1544232-f0008){#F7}

  REAGENT or RESOURCE                                                   SOURCE                                                                                                   IDENTIFIER
  --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                                                     
  Mouse anti-CD8, clone C8/144B                                         Esbe/Cell Marque, Rocklin, CA                                                                            Cat\#108M-94; RRID: AB_1158205
  Rabbit anti-CD3, clone SP7                                            Abcam (Supplier Spring Bioscience)                                                                       Cat\#ab16669; RRID: AB_443425
  Mouse anti-PD-L1, clone SP142                                         Abcam (Supplier Spring Bioscience)                                                                       Cat\#ab228462
  Mouse anti-CD68, clone KP-1                                           Biocare Medical (Distributed by Intermedico), Pacheco, CA                                                Cat\#CM033
  Rabbit anti-PD1, clone EPR4877(2)                                     Abcam                                                                                                    Cat\#ab137132
  Biological Samples                                                                                                                                                             
  Primary tumor samples                                                 Multiple tissue source sites, processed through the Biospecimen and Library Construction Core Resource   See [STAR Methods](#S11){ref-type="sec"} and [Table S1](#SD3){ref-type="supplementary-material"}.
  Critical Commercial Assays                                                                                                                                                     
  Infinium MethylationEPIC BeadChip                                     Illumina                                                                                                 WG-317--1001
  Deposited Data                                                                                                                                                                 
  Raw DNA methylation data (ATRT cases from DKFZ)                       This paper                                                                                               GEO Accession: GSE123601
  Raw DNA methylation data (MRT cases from TARGET)                      This paper                                                                                               NCBI dbGaP Accession: phs000470
  Raw sequencing data from TARGET MRT cases                             This paper                                                                                               NCBI dbGaP Accession: phs000470
  Processed data from TARGET MRT cases                                  This paper                                                                                               <http://target.nci.nih.gov/dataMatrix/TARGETDataMatrix.html>
  Raw sequencing data previously generated from MRT cases               [@R16]                                                                                                   NCBI dbGaP Accession: phs000470
  Processed data previously generated from MRT cases                    [@R16]                                                                                                   <http://target.nci.nih.gov/dataMatrix/TARGETDataMatrix.html>
  Raw sequencing data previously generated from ATRT cases              [@R38]                                                                                                   EGA Study Accession: EGAS00001001297
  Raw DNA methylation array data previously generated from ATRT cases   [@R38]                                                                                                   GEO Accession: GSE70460
  Raw gene-expression array data previously generated from ATRT cases   [@R38]                                                                                                   GEO Accession: GSE70678
  Software and Algorithms                                                                                                                                                        
  BWA v0.5.7                                                            [@R45]                                                                                                   <http://bio-bwa.sourceforge.net/>; RRID:SCR_010910
  Picard v1.71                                                          <https://broadinstitute.github.io/picard/>                                                               RRID:SCR_006525
  SAMtools v0.1.17                                                      [@R46]                                                                                                   <http://samtools.sourceforge.net/>; RRID:SCR_002105
  Strelka v2.0.7                                                        [@R64]                                                                                                   <ftp://strelka@ftp.illumina.com/>; RRID:SCR_005109
  MutationSeq                                                           [@R18]                                                                                                   <http://www.shahlab.ca>; RRID:SCR_006815
  APOLLOH v012.2014a                                                    [@R23]                                                                                                   <https://shahlab.ca/projects/apolloh/>; RRID:SCR_006648
  ABySS v1.4.10                                                         [@R62]                                                                                                   <http://www.bcgsc.ca/platform/bioinfo/software/>; RRID:SCR_010709
  CNASeq v1.0.10                                                        [@R39]                                                                                                   <https://www.bcgsc.ca/one/login.cgi?came_from=http%3A//www.bcgsc.ca/platform/bioinfo/software/cnaseq>
  JAGuaR v2.2.2                                                         [@R10]                                                                                                   <http://www.bcgsc.ca/platform/bioinfo/software/jaguar>
  DESeq R package v1.26.0                                               [@R2]                                                                                                    <https://bioconductor.org/packages/release/bioc/html/DESeq.html>; RRID:SCR_000154
  NMF R package v0.20.6                                                 [@R21]                                                                                                   <https://cran.r-project.org/web/packages/NMF/index.html>
  Minfi R package v1.20.2                                               [@R3]                                                                                                    <https://bioconductor.org/packages/release/bioc/html/minfi.html>; RRID:SCR_012830
  GVIZ R package v1.26.4                                                [@R24]                                                                                                   <https://bioconductor.org/packages/release/bioc/html/Gviz.html>
  Pheatmap R package v.1.0.10                                           <https://cran.r-project.org/web/packages/pheatmap/index.html>                                            RRID:SCR_016418
  Bsseq R package v1.18.0                                               [@R25]                                                                                                   <http://www.bioconductor.org/packages/2.13/bioc/html/bsseq.html>; RRID:SCR_001072
  HOMER v4.10                                                           [@R27]                                                                                                   <http://homer.ucsd.edu/homer/>; RRID:SCR_010881
  inForm Cell Analysis                                                  PerkinElmer                                                                                              <https://www.perkinelmer.com/product/inform-cell-analysis-one-seat-cls135781>
  CIBERSORT v1.04                                                       [@R54]                                                                                                   <https://cibersort.stanford.edu/>; RRID:SCR_016955
  MiXCR v2.1.9                                                          [@R6]                                                                                                    <https://mixcr.readthedocs.io/en/master/>
  MACS2                                                                 [@R78]                                                                                                   <https://github.com/taoliu/MACS>; RRID:SCR_013291
  Bismark                                                               [@R40]                                                                                                   <https://www.bioinformatics.babraham.ac.uk/projects/bismark/>; RRID:SCR_005604

###### Highlights

-   MYC subgroup of cranial RTs (ATRT-MYC) is molecularly similar to extra-cranial RTs

-   Five DNA methylation subgroups are identified in RTs across multiple organ sites

-   Groups 1, 3, and 4 exhibit cytotoxic T cell infiltration and PD1 and PD-L1 expression
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